Several articles have suggested that sarcopenia is correlated with poor clinical outcomes in patients receiving PD-1/PD-L1 inhibitors (12, 13), however, other researches have reached inconsistent conclusions (14–16). The gene discussed is CD274; the disease is sarcopenia.